Answers are grounded in this paper and cite their sources.
Comparative case series reports distinct presentations of pediatric Xp11 translocation renal cell carcinoma, highlighting the necessity of TFE3 screening and long-term surveillance.
A BSTRACT Renal cell carcinoma (RCC) is rare in the pediatric age group, accounting for <5% of all childhood renal malignancies. Among these, Xp11 translocation-associated RCC is a distinct molecular subtype characterized by TFE3 gene rearrangement and unique clinicopathological features. Because it mimics features of more common pediatric tumors on imaging, definitive diagnosis can be challenging. We report and contrast two distinct pediatric presentations of Xp11 translocation RCC in female patients. Case 1 involves a 10-year-old girl presenting with abdominal pain and a palpable right flank mass. Case 2 describes a 5-year-old girl presenting with acute gross hematuria and clot passage. Both patients underwent radical surgical intervention (radical nephrectomy and nephroureterectomy with extensive lymph node sampling, respectively). Histopathological examination revealed distinct morphologic patterns, with a papillary architecture in Case 1 and a nested pattern with psammoma bodies in Case 2. Both tumors demonstrated strong nuclear TFE3 immunoreactivity, confirming Xp11 translocation-associated RCC. Case 1 was managed by close observation alone, while Case 2 received 15 months of adjuvant tyrosine kinase inhibitor (Sunitinib) therapy. Localized pediatric Xp11 translocation RCC carries a favorable prognosis when completely resected, but its unpredictable biological behavior necessitates standardizing immunohistochemical screening alongside definitive long-term surveillance.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: